Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A form of LEISHMANIASIS, CUTANEOUS caused by Leishmania aethiopica in Ethiopia and Kenya, L. pifanoi in Venezuela, L. braziliensis in South America, and L. mexicana in Central America. This disease is characterized by massive dissemination of skin lesions without visceral involvement.
Biomarker and diagnostic research for leishmaniasis, diffuse cutaneous has been reported in the published literature.
No clinical trials have been registered for leishmaniasis, diffuse cutaneous.
43 publications have been identified in PubMed for leishmaniasis, diffuse cutaneous. Research spans Case Report / Case Series (30%), Basic Science / Preclinical (23%), and Review / Meta-Analysis (19%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 13 | 30% |
Data assembled from 2 of 12 sources · Last updated Sep 19, 2026, 12:47 AM UTC
Laboratory research
10 |
23% |
Research summaries | 8 | 19% |
Disease patterns and progression | 5 | 12% |
Clinical study results | 3 | 7% |
New treatment approaches | 2 | 5% |
Other research | 1 | 2% |
Testing and diagnosis research | 1 | 2% |
Fernandes JMP (2026). [PMID: 42159794](https://pubmed.ncbi.nlm.nih.gov/42159794/). *Parasitol Res*. [Basic Science / Preclinical]
de Sousa Agostino V (2026). [PMID: 41754472](https://pubmed.ncbi.nlm.nih.gov/41754472/). *Pathogens*. [Basic Science / Preclinical]
Portugal AB (2026). [PMID: 41500977](https://pubmed.ncbi.nlm.nih.gov/41500977/). *Parasite Immunol*. [Review / Meta-Analysis]
Doni SN (2026). [PMID: 41701626](https://pubmed.ncbi.nlm.nih.gov/41701626/). *Br J Dermatol*. [Epidemiology / Natural History]
Phadungsaksawasdi K (2026). [PMID: 41731636](https://pubmed.ncbi.nlm.nih.gov/41731636/). *Trop Med Health*. [Gene Therapy / Novel Therapeutics]
Miguel DC (2026). [PMID: 41802553](https://pubmed.ncbi.nlm.nih.gov/41802553/). *Acta Trop*. [Basic Science / Preclinical]
Lopes PO (2026). [PMID: 41317893](https://pubmed.ncbi.nlm.nih.gov/41317893/). *J Invest Dermatol*. [Basic Science / Preclinical]
Teixeira MdM (2026). [PMID: 42132385](https://pubmed.ncbi.nlm.nih.gov/42132385/). *Clin Microbiol Rev*. [Review / Meta-Analysis]
Pham TT (2026). [PMID: 41540511](https://pubmed.ncbi.nlm.nih.gov/41540511/). *Infect Dis Poverty*. [Review / Meta-Analysis]
Freitas CS (2026). [PMID: 41964514](https://pubmed.ncbi.nlm.nih.gov/41964514/). *Cell Biochem Funct*. [Review / Meta-Analysis]
AI-curated news mentioning leishmaniasis, diffuse cutaneous
Updated May 11, 2026
Research reveals that eprinomectin effectively inhibits Leishmania by inducing mitochondrial dysfunction and causing cell cycle arrest. This discovery could pave the way for new therapeutic strategies against leishmaniasis.
A recent study explores local cytokine modulation and parasite visceralization in mice coinfected with Leishmania amazonensis and Schistosoma mansoni. This research provides insights into the immune response mechanisms during dual infections.
A study reports the first imported case of New World leishmaniasis in Romania, highlighting diagnostic and therapeutic challenges in a non-endemic region. This case underscores the need for increased awareness and preparedness for rare diseases in areas where they are not typically found.